Jump Financial LLC Purchases 273,493 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Jump Financial LLC lifted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 128.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 487,103 shares of the company's stock after acquiring an additional 273,493 shares during the period. Jump Financial LLC's holdings in Teva Pharmaceutical Industries were worth $10,736,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently modified their holdings of the business. Stifel Financial Corp increased its holdings in shares of Teva Pharmaceutical Industries by 54.0% during the third quarter. Stifel Financial Corp now owns 66,391 shares of the company's stock worth $1,196,000 after buying an additional 23,283 shares in the last quarter. Robeco Institutional Asset Management B.V. increased its holdings in Teva Pharmaceutical Industries by 7.2% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company's stock valued at $10,983,000 after purchasing an additional 33,277 shares during the period. Pinnbrook Capital Management LP bought a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $4,966,000. Asset Management One Co. Ltd. raised its holdings in Teva Pharmaceutical Industries by 14.6% during the 4th quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company's stock worth $10,414,000 after purchasing an additional 58,413 shares during the last quarter. Finally, CWA Asset Management Group LLC bought a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at $3,340,000. Institutional investors and hedge funds own 54.05% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on TEVA shares. UBS Group cut their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. Piper Sandler upped their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. Barclays dropped their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, January 30th. Bank of America reduced their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a report on Thursday, March 6th. Finally, StockNews.com lowered Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Monday, April 14th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $23.43.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA traded up $0.18 during trading on Friday, reaching $13.61. 8,836,138 shares of the stock traded hands, compared to its average volume of 9,902,722. The company has a 50-day moving average of $15.45 and a 200-day moving average of $17.67. Teva Pharmaceutical Industries Limited has a 52-week low of $12.47 and a 52-week high of $22.80. The stock has a market capitalization of $15.43 billion, a P/E ratio of -9.38, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.